Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received an average rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $66.13.

Several equities research analysts recently commented on the stock. Scotiabank cut their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Monday, September 16th. Stifel Nicolaus began coverage on Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a research report on Monday, August 19th. Finally, Wedbush reissued an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a report on Thursday, August 8th.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $49.55 on Monday. Janux Therapeutics has a 1 year low of $5.65 and a 1 year high of $65.60. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of -40.61 and a beta of 3.54. The business has a 50-day moving average of $44.42 and a two-hundred day moving average of $44.96.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to the consensus estimate of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. Janux Therapeutics’s revenue for the quarter was up 709.1% compared to the same quarter last year. As a group, equities research analysts expect that Janux Therapeutics will post -1.18 earnings per share for the current year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the completion of the transaction, the insider now owns 3,162,851 shares in the company, valued at approximately $132,839,742. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the transaction, the insider now owns 3,162,851 shares in the company, valued at approximately $132,839,742. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Andrew Hollman Meyer sold 50,000 shares of the business’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the sale, the insider now owns 67,592 shares in the company, valued at $3,106,528.32. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 393,767 shares of company stock worth $17,857,979 in the last three months. Insiders own 35.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of JANX. Summit Securities Group LLC purchased a new position in Janux Therapeutics during the 2nd quarter valued at about $29,000. Amalgamated Bank increased its stake in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares in the last quarter. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $42,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Janux Therapeutics in the 2nd quarter valued at approximately $151,000. Finally, AQR Capital Management LLC acquired a new stake in Janux Therapeutics during the 2nd quarter valued at $215,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.